Hepatocyte‐specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure

Ying Chen, Yi Yang, Marian L. Miller, Dongxiao Shen, Howard G. Shertzer, Keith F. Stringer, Bin Wang, Scott N. Schneider, Daniel W. Nebert, Timothy P. Dalton – 26 April 2007 – Oxidative stress is considered to be a critical mediator in liver injury of various etiologies. Depletion of glutathione (GSH), the major antioxidant in liver, has been associated with numerous liver diseases.

Incidence and risk factors for gallstones in patients with inflammatory bowel disease: A large case‐control study

Fabrizio Parente, Luca Pastore, Stefano Bargiggia, Claudia Cucino, Salvatore Greco, Mirko Molteni, Sandro Ardizzone, Gabriele Bianchi Porro, Gianluca M. Sampietro, Riccardo Giorgi, Roberto Moretti, Silvano Gallus – 26 April 2007 – The risk for gallstones (GD) in inflammatory bowel diseases and the factors responsible for this complication have not been well established. We studied the incidence of GD in a cohort of Crohn's disease (CD) and ulcerative colitis (UC) patients and investigated the related risk factors. A case‐controlled study was carried out.

Twenty‐four‐week clevudine therapy showed potent and sustained antiviral activity in HBeAg‐positive chronic hepatitis B

Byung Chul Yoo, Ju Hyun Kim, Young‐Hwa Chung, Kwan Sik Lee, Seung Woon Paik, Soo Hyung Ryu, Byung Hoon Han, Joon‐Yeol Han, Kwan Soo Byun, Mong Cho, Heon‐Ju Lee, Tae‐Hun Kim, Se‐Hyun Cho, Joong‐Won Park, Soon‐Ho Um, Seong Gyu Hwang, Young Soo Kim, Youn‐Jae Lee, Chae Yoon Chon, Byung‐Ik Kim, Young‐Suk Lee, Jin‐Mo Yang, Haak Cheoul Kim, Jae Seok Hwang, Sung‐Kyu Choi, Young‐Oh Kweon, Sook‐Hyang Jeong, Myung‐Seok Lee, Jong‐Young Choi, Dae‐Ghon Kim, Yun Soo Kim, Heon Young Lee, Kwon Yoo, Hee‐Won Yoo, Hyo‐Suk Lee – 26 April 2007 – Clevudine is a pyrimidine analogue with potent and sustained antivi

Molecular pathogenesis of alpha‐1‐antitrypsin deficiency‐associated liver disease: A meeting review

David H. Perlmutter, Jeffrey L. Brodsky, William F. Balistreri, Bruce C. Trapnell – 26 April 2007 – In recent years, we have witnessed several important paradigm shifts in understanding the molecular basis of liver disease in alpha‐1‐antitrypsin (AT) deficiency. These shifts have become possible as a result of a number of advances in research on the cell biology of aggregation‐prone mutant proteins and in research on the pathobiological mechanisms of liver disease in general.

HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long‐term follow‐up

Chia‐Ming Chu, Yun‐Fan Liaw – 26 April 2007 – Spontaneous hepatitis B surface antigen (HBsAg) seroclearance in chronic HBV infection has long been suggested as a rare event in high endemic areas. The prevalence of HBsAg in the general population of Taiwan, however, decreased remarkably from 15%‐20% before age 40 to 5%‐10% after age 60 or 70. This study aimed to reexamine the rates of HBsAg seroclearance by a long‐term follow‐up of 1965 hepatitis B e antibody–positive asymptomatic adult carriers.

Differential regulation of constitutive androstane receptor expression by hepatocyte nuclear factor4α isoforms

Jean Marc Pascussi, Agnes Robert, Amelie Moreau, Jeanne Ramos, Paulette Bioulac‐Sage, Francis Navarro, Pierre Blanc, Eric Assenat, Patrick Maurel, Marie Jose Vilarem – 26 April 2007 – Constitutive androstane receptor (CAR; NR1I3) controls the metabolism and elimination of endogenous and exogenous toxic compounds by up‐regulating a battery of genes.

Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis

Jean‐Baptiste Nousbaum, Jean‐François Cadranel, Pierre Nahon, Eric Nguyen Khac, Richard Moreau, Thierry Thévenot, Christine Silvain, Christophe Bureau, Olivier Nouel, Christophe Pilette, Thierry Paupard, Geoffroy Vanbiervliet, Frédéric Oberti, Thierry Davion, Vincent Jouannaud, Bruno Roche, Pierre‐Henri Bernard, Sandrine Beaulieu, Odile Danne, Dominique Thabut, Carinne Chagneau‐Derrode, Victor de Lédinghen, Philippe Mathurin, Arnaud Pauwels, Jean‐Pierre Bronowicki, François Habersetzer, Armand Abergel, Jean‐Christian Audigier, Thierry Sapey, Jean‐Didier Grangé, Albert Tran – 26 April 2007 –

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C

Robert J. Fontana, Linas A. Bieliauskas, Karen L. Lindsay, Carla Back‐Madruga, Elizabeth C. Wright, Kristin K. Snow, Anna S.F. Lok, Ziad Kronfol, Latha Padmanabhan – 26 April 2007 – Treatment of chronic hepatitis C with pegylated interferon (peginterferon) and ribavirin can cause or exacerbate depression but its effects on cognitive function are largely unknown. The aim of this study was to determine whether treatment with peginterferon and ribavirin adversely impacts cognitive function in patients with chronic hepatitis C.

Subscribe to